Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand

Viriya Hantrakun, Wirongrong Chierakul, Ploenchan Chetchotisakd, Siriluck Anunnatsiri, Bart J. Currie, Sharon J. Peacock, Nicholas P.J. Day, Phaik Cheah, Direk Limmathurotsakul, Yoel Lubell

    Research output: Contribution to journalArticlepeer-review


    Background: Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking. 

    Methods: A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem. 

    Results: Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%. 

    Conclusions: In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available.

    Original languageEnglish
    Pages (from-to)416-418
    Number of pages3
    JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
    Issue number6
    Publication statusPublished - 2015


    Dive into the research topics of 'Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand'. Together they form a unique fingerprint.

    Cite this